The pharmaceutical industry have, in recent years, focused on development of so-called specialty drugs and have priced them aggressively. These prices, such as the US$1,000 per pill price for the hepatitis C drug sofosbuvir, are alarming for patients, employers, insurers, and governments.
“The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.”
Our effort—the Campaign for Sustainable Rx Prices—has been sounding the alarm for more than a year that pharmaceutical companies must come to the table with meaningful solutions to the challenge of rising drug costs. Otherwise, companies risk the rising tide of consumer anger resulting in solutions that are not constructive for anyone.
PRESS STATEMENT For Immediate Release August 20, 2015 Contact: John Rother [email protected] New KFF Poll: Unsustainable drug pricing moves ahead of ACA as GOP voters’ top health care concern A new poll released today by the Kaiser Family Foundation finds overwhelming bipartisan majorities of voters are concerned about the challenges to affordability for consumers posed […]
This is an important time to think about the future of programs and policies that support us as we age. Medicare marks its 50th Anniversary at the end of July. I’ve been around to witness much of the creation and evolution of health policy. After a 40-year career in Aging and Health Policy, first in the Senate, then at AARP, and now as head of the National Coalition on Health Care, I have a few observations about where things stand.
“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.”
“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”
PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices
Exorbitant price tags for specialty medications are taking a serious financial toll on state budgets. A new analysis released yesterday from the California Association of Health Plans (CAHP) shows that treating only 10 percent of 175,000 patients in state-funded health care programs with just three hepatitis C medications would cost California roughly $1-2 billion.
John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.